The evolving treatment paradigm for BRAF V600 mutant colorectal cancer

Jeremy D Kratz¹, Dustin A Deming^{1

2

3}

Affiliations

¹ Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
² Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
³ University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Editorial

Jeremy D Kratz et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S257.

doi: 10.21037/atm.2019.12.61.

Jeremy D Kratz¹, Dustin A Deming^{1

2

3}

¹ Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
² Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
³ University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: Dr. Kratz has no conflicts of interest to declare. Dr. Deming has served on an advisory board for Array BioPharma.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Van Cutsem E, et al. J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892987 Free PMC article. Clinical Trial.

1. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7. 10.1038/nature11252 - DOI - PMC - PubMed
1. Loupakis F, Moretto R, Aprile G, et al. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. Br J Cancer 2016;114:30-6. 10.1038/bjc.2015.399 - DOI - PMC - PubMed
1. Innocenti F, Ou FS, Zemla T, et al. Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). American Society of Clinical Oncology, 2017.
1. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16:1306-15. 10.1016/S1470-2045(15)00122-9 - DOI - PubMed
1. Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75. 10.1016/j.ejca.2012.02.057 - DOI - PubMed